However, the expression of PD-L1 on DCs in ovarian cancer patients is moderate compared with on normal ovarian tissues (83), and currently, there is no clinical trial testing the combination of anti-PD-1/PD-L1 and DC vaccines. This evidence concerns the gene PDCD1 and ovarian carcinoma.